Ioannis N. Anastopoulos

发表

CODEX2: full-spectrum copy number variation detection by high-throughput DNA sequencing

Nancy R. Zhang, K. Nathanson, Yuchao Jiang, 2017, bioRxiv.

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

Sydney M. Shaffer, A. Raj, M. Herlyn, 2017, Nature.

Using Transcriptional Signatures to Find Cancer Drivers with LURE

Joshua M. Stuart, Christopher K. Wong, D. Haan, 2019, bioRxiv.

CODEX2: full-spectrum copy number variation detection by high-throughput DNA sequencing

Nancy R. Zhang, Yuchao Jiang, Eugene Urrutia, 2017, Genome Biology.

Multi-Drug Featurization and Deep Learning Improve Patient-Specific Predictions of Adverse Events

Atray Dixit, Ioannis N. Anastopoulos, K. Davis, 2021, International journal of environmental research and public health.

Towards inferring nanopore sequencing ionic currents from nucleotide chemical structures

Joshua M. Stuart, B. Paten, Hongxu Ding, 2020, Nature Communications.

Patient Informed Domain Adaptation Improves Clinical Drug Response Prediction

Joshua M. Stuart, Hongxu Ding, Ioannis N. Anastopoulos, 2021, bioRxiv.

Hydra: A mixture modeling framework for subtyping pediatric cancer cohorts using multimodal gene expression signatures

David Haussler, Holly C Beale, Lauren M Sanders, 2020, PLoS Comput. Biol..

VEGA is an interpretable generative model for inferring biological network activity in single-cell transcriptomics

Joshua M. Stuart, Hongxu Ding, Ioannis N. Anastopoulos, 2021, Nature Communications.

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers

Nancy R. Zhang, K. Nathanson, M. Feldman, 2017, Nature Communications.

Biological network-inspired interpretable variational autoencoder

Joshua M. Stuart, Lucas Seninge, I. Anastopoulos, 2020 .

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Yiling Lu, Lauren E Haydu, Gordon B Mills, 2017, Cell reports.

Corrigendum: Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

A. Raj, M. Herlyn, Abhyudai Singh, 2018, Nature.

Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines.

Nancy R. Zhang, D. Elder, C. Shields, 2017, Cell reports.

Correction: Anastopoulos et al. Multi-Drug Featurization and Deep Learning Improve Patient-Specific Predictions of Adverse Events. Int. J. Environ. Res. Public Health 2021, 18, 2600

Ioannis N. Anastopoulos, K. Davis, C. Herczeg, 2022, International journal of environmental research and public health.

Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines

Ioannis N. Anastopoulos, C. Krepler, Bradley Garman, 2020 .